Show simple item record

dc.contributor.authorOrozco, Carlos A
dc.contributor.authorMartinez-Bosch, Neus
dc.contributor.authorGuerrero, Pedro E
dc.contributor.authorVinaixa, Judith
dc.contributor.authorDalotto-Moreno, Tomás
dc.contributor.authorIglesias, Mar
dc.contributor.authorMoreno, Mireia
dc.contributor.authorDjurec, Magdolna
dc.contributor.authorPoirier, Françoise
dc.contributor.authorGabius, Hans-Joachim
dc.contributor.authorFernandez-Zapico, Martin E
dc.contributor.authorHwang, Rosa F
dc.contributor.authorGuerra, Carmen 
dc.contributor.authorRabinovich, Gabriel A
dc.contributor.authorNavarro, Pilar
dc.date.accessioned2019-09-20T11:45:55Z
dc.date.available2019-09-20T11:45:55Z
dc.date.issued2018-04-17
dc.identifier.citationProc Natl Acad Sci U S A. 2018 ;115(16):E3769-E3778.es_ES
dc.identifier.issn0027-8424es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8359
dc.description.abstractPancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with extremely low survival rates due to late diagnosis and resistance to standard therapies. A more comprehensive understanding of the complexity of PDA pathobiology, and especially of the role of the tumor microenvironment in disease progression, should pave the way for therapies to improve patient response rates. In this study, we identify galectin-1 (Gal1), a glycan-binding protein that is highly overexpressed in PDA stroma, as a major driver of pancreatic cancer progression. Genetic deletion of Gal1 in a Kras-driven mouse model of PDA (Ela-KrasG12Vp53 -/- ) results in a significant increase in survival through mechanisms involving decreased stroma activation, attenuated vascularization, and enhanced T cell infiltration leading to diminished metastasis rates. In a human setting, human pancreatic stellate cells (HPSCs) promote cancer proliferation, migration, and invasion via Gal1-driven pathways. Moreover, in vivo orthotopic coinjection of pancreatic tumor cells with Gal1-depleted HPSCs leads to impaired tumor formation and metastasis in mice. Gene-expression analyses of pancreatic tumor cells exposed to Gal1 reveal modulation of multiple regulatory pathways involved in tumor progression. Thus, Gal1 hierarchically regulates different events implicated in PDA biology including tumor cell proliferation, invasion, angiogenesis, inflammation, and metastasis, highlighting the broad therapeutic potential of Gal1-specific inhibitors, either alone or in combination with other therapeutic modalities.es_ES
dc.description.sponsorshipCKNOWLEDGMENTS. We thank J. M. Caballero (PRBB Animal Facility) and the staffs of the UPF Flow Cytometry and the IMIM microarray core facilities for helpful technical assistance, Raul Peña and the Epithelial-to-Mesenchymal Transition and Cancer Progression group (IMIM) for providing reagents and valuable technical help, and V. A. Raker for English proofreading and manu- script editing. Images for figure preparation were provided by SMART (Servier Medical Art, https://smart.servier.com/ ). This work was supported by Spanish Ministry of Economy and Competitiveness/ISCIII-FEDER Grants PI14/00125 and PI17/00199, the Carmen Delgado/Miguel Pérez-Mateo Asociación Española de Pancreatología/ Asociación Cáncer de Páncreas 2016 Grant, and Generalitat de Catalunya Grant 2014/SGR/143 (to P.N.). M.E.F.-Z. was supported by Mayo Clinic Pancreatic Specialized Program of Research Excellence Grant P50 CA102701 and Mayo Clinic Center for Cell Signaling in Gastroenterology Grant P30 DK84567. C.A.O. was supported by the International PhD Studies Fellowship Créditos Beca Francisco José de Caldas from the Colombian Administrative Department of Science, Technology and Innovation (Colciencias). M.D. was supported by a fellowship from La Caixa International Fellowship Program. G.A.R. was supported by Argentinean Agency for Promotion of Science and Technology Grant PICT 2014-3687 and by grants from the University of Buenos Aires, the Sales Foundation, and the Bunge and Born Foundation. T.D.-M. is a postdoctoral fellow supported by the Argentine National Scientific and Tech- nical Research Counciles_ES
dc.language.isoenges_ES
dc.publisherNATL ACAD SCIENCESes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectgalectin-1es_ES
dc.subjectpancreatic canceres_ES
dc.subjectpancreatic stellate cellses_ES
dc.subjecttumor immunityes_ES
dc.subjecttumor microenvironmentes_ES
dc.subject.meshAnimals es_ES
dc.subject.meshCarcinoma, Pancreatic Ductal es_ES
dc.subject.meshCell Division es_ES
dc.subject.meshCell Movement es_ES
dc.subject.meshCulture Media, Conditioned es_ES
dc.subject.meshGalectin 1 es_ES
dc.subject.meshGalectins es_ES
dc.subject.meshGene Expression Regulation, Neoplastic es_ES
dc.subject.meshGene Knockdown Techniques es_ES
dc.subject.meshGene Ontology es_ES
dc.subject.meshHeterografts es_ES
dc.subject.meshHumans es_ES
dc.subject.meshLymphocytes, Tumor-Infiltrating es_ES
dc.subject.meshMice es_ES
dc.subject.meshMice, Knockout es_ES
dc.subject.meshMice, Transgenic es_ES
dc.subject.meshNeoplasm Metastasis es_ES
dc.subject.meshNeovascularization, Pathologices_ES
dc.subject.meshPancreatic Neoplasms es_ES
dc.subject.meshPancreatic Stellate Cells es_ES
dc.subject.meshParacrine Communication es_ES
dc.subject.meshRNA, Small Interfering es_ES
dc.subject.meshStromal Cells es_ES
dc.subject.meshTumor Microenvironment es_ES
dc.subject.meshMolecular Targeted Therapy es_ES
dc.titleTargeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalkes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID29615514es_ES
dc.format.volume115es_ES
dc.format.number16es_ES
dc.format.pageE3769-E3778es_ES
dc.identifier.doi10.1073/pnas.1722434115es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.contributor.funderAsociacion Española de Pancreatologiaes_ES
dc.contributor.funderGeneralitat de Catalunyaes_ES
dc.contributor.funderColombian Administrative Department of Science, Technology and Innovation (Colciencias)es_ES
dc.contributor.funderUniversity of Buenos Aireses_ES
dc.contributor.funderSales Foundationes_ES
dc.contributor.funderBunge and Born Foundationes_ES
dc.contributor.funderArgentine National Scientific and Technical Research Counciles_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1091-6490es_ES
dc.relation.publisherversionhttps://doi.org/10.1073/pnas.1722434115.es_ES
dc.identifier.journalProceedings of the National Academy of Sciences of the United States of Americaes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Oncología Experimentales_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/00125es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00199es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional